| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/20/2023 | 36.99% | Exane BNP Paribas | → $5 | Initiates Coverage On | → Neutral |
| 10/17/2023 | 91.79% | Morgan Stanley | $8 → $7 | Maintains | Equal-Weight |
| 10/06/2023 | 9.59% | Piper Sandler | $5 → $4 | Maintains | Neutral |
| 09/08/2023 | 365.77% | Evercore ISI Group | $11 → $17 | Maintains | Outperform |
| 09/06/2023 | 119.18% | Morgan Stanley | $12 → $8 | Downgrades | Overweight → Equal-Weight |
| 08/30/2023 | 64.39% | Barclays | → $6 | Initiates Coverage On | → Equal-Weight |
| 07/20/2023 | 64.39% | B of A Securities | $5 → $6 | Maintains | Underperform |
| 06/23/2023 | 64.39% | Piper Sandler | → $6 | Initiates Coverage On | → Neutral |
| 06/14/2023 | 228.78% | Morgan Stanley | → $12 | Reiterates | → Overweight |
| 06/06/2023 | 228.78% | Janney Montgomery Scott | → $12 | Initiates Coverage On | → Buy |
| 05/24/2023 | 201.38% | Evercore ISI Group | → $11 | Initiates Coverage On | → Outperform |
| 04/06/2023 | 160.28% | UBS | $18 → $9.5 | Maintains | Buy |
| 04/06/2023 | — | Wolfe Research | Downgrades | Outperform → Peer Perform | |
| 04/04/2023 | 36.99% | B of A Securities | $9 → $5 | Downgrades | Neutral → Underperform |
| 04/03/2023 | 228.78% | Morgan Stanley | $15 → $12 | Maintains | Overweight |
| 03/30/2023 | 228.78% | Susquehanna | $17 → $12 | Maintains | Positive |
| 03/30/2023 | 228.78% | Goldman Sachs | $14 → $12 | Maintains | Buy |
| 02/21/2023 | 283.57% | Goldman Sachs | $16 → $14 | Maintains | Buy |
| 02/21/2023 | 447.96% | Credit Suisse | $24 → $20 | Maintains | Outperform |
| 02/17/2023 | 365.77% | Susquehanna | $20 → $17 | Maintains | Positive |
| 02/10/2023 | 201.38% | B of A Securities | → $11 | Initiates Coverage On | → Neutral |
| 01/10/2023 | 310.97% | Morgan Stanley | → $15 | Upgrades | Equal-Weight → Overweight |
| 12/20/2022 | 338.37% | Goldman Sachs | $18 → $16 | Maintains | Buy |
| 10/25/2022 | 420.56% | UBS | → $19 | Initiates Coverage On | → Buy |
| 09/29/2022 | 447.96% | Cowen & Co. | $22 → $20 | Maintains | Outperform |
| 09/29/2022 | 475.36% | Morgan Stanley | $20 → $21 | Maintains | Equal-Weight |
| 09/22/2022 | 502.76% | Cowen & Co. | → $22 | Initiates Coverage On | → Outperform |
| 09/07/2022 | 557.55% | Northland Capital Markets | → $24 | Initiates Coverage On | → Outperform |
| 08/18/2022 | 447.96% | Morgan Stanley | $13 → $20 | Maintains | Equal-Weight |
| 03/23/2022 | 256.17% | Morgan Stanley | → $13 | Initiates Coverage On | → Equal-Weight |
| 03/22/2022 | 338.37% | Guggenheim | → $16 | Initiates Coverage On | → Buy |
| 11/22/2021 | 858.93% | Wolfe Research | → $35 | Initiates Coverage On | → Outperform |
| 07/19/2021 | 858.93% | Susquehanna | → $35 | Initiates Coverage On | → Positive |
| 06/29/2021 | 1215.1% | Credit Suisse | → $48 | Initiates Coverage On | → Outperform |
| 05/24/2021 | 721.94% | Goldman Sachs | → $30 | Initiates Coverage On | → Buy |
What is the target price for Stem (STEM)?
The latest price target for Stem (NYSE: STEM) was reported by Exane BNP Paribas on October 20, 2023. The analyst firm set a price target for $5.00 expecting STEM to rise to within 12 months (a possible 36.99% upside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Stem (STEM)?
The latest analyst rating for Stem (NYSE: STEM) was provided by Exane BNP Paribas, and Stem initiated their neutral rating.
When is the next analyst rating going to be posted or updated for Stem (STEM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Stem, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Stem was filed on October 20, 2023 so you should expect the next rating to be made available sometime around October 20, 2024.
Is the Analyst Rating Stem (STEM) correct?
While ratings are subjective and will change, the latest Stem (STEM) rating was a initiated with a price target of $0.00 to $5.00. The current price Stem (STEM) is trading at is $3.65, which is within the analyst's predicted range.